MDGL250117C360000
- 10.75
- +3.75+53.57%
Madrigal Pharmaceuticals Newsroom
Madrigal Pharmaceuticals Analyst Ratings
Madrigal Pharmaceuticals' Rezdiffra Shows Strong Market Growth and Positive Outlook, Justifying Buy Rating
JMP Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Raises Target Price to $427
BofA Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Sell Rating, Announces Target Price $155
Leerink Partners Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $390
Analysts Are Bullish on Top Healthcare Stocks: Axsome Therapeutics (AXSM), Madrigal Pharmaceuticals (MDGL)
Oppenheimer Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Raises Target Price to $400
Madrigal Pharmaceuticals Analyst Ratings
TD Cowen Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $390
TD Cowen Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $390
Madrigal Pharmaceuticals Is Maintained at Neutral by B. Riley Securities
Madrigal Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Travere Therapeutics (TVTX) and Regeneron (REGN)
Jefferies Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $400
Jefferies Keeps Their Buy Rating on Madrigal Pharmaceuticals (MDGL)
A Quick Look at Today's Ratings for Madrigal Pharmaceuticals(MDGL.US), With a Forecast Between $350 to $441
Madrigal Pharmaceuticals Analyst Ratings
UBS Adjusts Price Target on Madrigal Pharmaceuticals to $441 From $411, Maintains Buy Rating
A Quick Look at Today's Ratings for Madrigal Pharmaceuticals(MDGL.US), With a Forecast Between $350 to $441
BofA Securities Initiates Madrigal Pharmaceuticals(MDGL.US) With Sell Rating